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Abstract
Background: Siah proteins play an important role in cancer progression. We evaluated the effect of Siah1, its
splice variants Siah1L and the Siah1 mutant with the RING finger deleted (Siah1ΔR) on radiosensitization of human
breast cancer cells.
Methods: The status of Siah1 and Siah1L was analysed in five breast cancer cell lines. To establish stable cells,
SKBR3 cells were transfected with Siah1, Siah-1L and Siah1ΔR. Siah1 function was suppressed by siRNA in MCF-7
cells. The impact of Siah1 overexpression and silencing on apoptosis, proliferation, survival, invasion ability and
DNA repair was assessed in SKBR3 and MCF-7 cells, also in regards to radiation.
Results: Siah1 and Siah1L mRNA expression was absent in four of five breast cancer cells lines analysed.
Overexpression of Siah1 and Siah1L enhanced radiation-induced apoptosis in stable transfected SKBR3 cells, while
Siah1ΔR failed to show this effect. In addition, Siah1 and Siah1L significantly reduced cell clonogenic survival and
proliferation. Siah1L sensitization enhancement ratio values were over 1.5 and 4.0 for clonogenic survival and
proliferation, respectively, pointing to a highly cooperative and potentially synergistic fashion with radiation. Siah1
or Siah1L significantly reduced invasion ability of SKBR3 and suppressed Tcf/Lef factor activity. Importantly, Siah1
siRNA demonstrated opposite effects in MCF-7 cells. Siah1 and Siah1L overexpression resulted in inhibition of DNA
repair as inferred by increased levels of DNA double-strand breaks in irradiated SKBR3 cells.
Conclusion: Our results reveal for the first time how overexpression of Siah1L and Siah1 can determine
radiosensitivity of breast cancer cells. These findings suggest that development of drugs augmenting Siah1 and
Siah1L activity could be a novel approach in improving tumor cell kill.
Background
Breast cancer is the most common malignancy and the
major cause of cancer-related deaths of women in
industrialized countries [1]. Radiotherapy consists one of
the cornerstones in the treatment of patients with breast
cancer and its role has been extensively studied during
the last decades [2,3]. Clinical studies have demon-
strated a major benefit of adjuvant radiotherapy in
increasing disease-free survival and overall survival. A
profound impact of ionizing radiation in improving local
control and reducing disease recurrence has also been
shown in patients undergoing breast-conserving therapy
[3]. However, radiotherapy is associated with side effects
including an increased risk of cardiovascular disease [4].
Finding agents that sensitize malignant cells to radiation
would therefore increase tumor response while minimiz-
ing toxicity to surrounding organs by lowering effective
therapeutic doses.
Regulation of protein stability through the ubiquitin-
proteasome pathway is now being recognized as a major
mechanism of regulating a diverse array of cellular pro-
cesses [5]. The Drosophila seven in absentia (Sina) pro-
tein and its human homolog Siah (seven in absentia
homolog) are members of an evolutionarily highly con-
served family of E3 ubiquitin ligases [6]. The members
of this family (Siah1 and Siah2) contain a N-terminal
RING domain that binds E2 proteins, followed by two
zinc-finger domains involved in protein-protein interac-
tions [6-8]. Siah ligases regulate the ubiquitination and
proteasomal degradation of several proteins including
DCC, b-catenin, c-Myb, alpha-synuclein, the CDK acti-
vator RINGO and BAG-1, a Hsp70/Hsc70-binding
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any medium, provided the original work is properly cited.protein, suggesting a role for Siah proteins in the regula-
tion of cell proliferation, migration, apoptosis and tumor
suppression [7-17]. Recent studies demonstrated that
lower expression of Siah2 was associated with resistance
to endocrine therapy in breast cancer [18]. Furthermore,
Siah2 expression predicated a favourable clinical out-
come of breast cancer patients [18,19]. Siah1 expression
is upregulated by p53, revealing a link between geno-
toxic injury and destruction of b-catenin [9,10,20] and
reduced T-cell factor/lymphoid enhancer factor (Tcf/
Lef) activity [11,18]. Furthermore, several Siah1 splicing
variants such Siah1L and Siah1 S involved in the degra-
dation of b-catenin degradation have been previously
described [21,22]. A recent study demonstrated a frame-
work of ATM/ATR and Siah1 through the stabilization
of HIPK2, a mediator of DNA-damage induced apopto-
sis, implicating Siah1 in DNA damage response [22,23].
Although Siah1 presents an attractive target for cancer
therapy, its potential radiosensitizing effects have not
been previously studied. In search for novel strategies to
enhance radiosensitivity of breast cancer, we investigated
the role of Siah1 and its related variant Siah1L on the
radiation response of SKBR3 and MCF-7 breast cancer
cells using different approaches. Furthermore, we ana-
lysed the impact of Siah1 overexpression on the biologic
behaviour of breast cancer cells by employing invasion
and Tcf/Lef reporter studies.
Methods
Plasmid Construction and Transfection
Siah1, Siah-1L and the Siah1 mutant with the RING
finger deleted that expresses Siah1ΔRw e r eg i f t sf r o m
P r o f .S IM a t s u z a w a ,t h eB u r n h a mI n s t i t u t e ,U S A[ 2 0 ] .
The Tcf/Lef-responsive luciferase reporter gene (Top-
flash), the negative control with mutated Tcf/Lef bind-
ing site (Fopflash), and the Renilla luciferase reporter
plasmid (pRL-TK) as an internal control were obtained
from Upstate Biotechnology, USA. The human breast
cancer cell lines BT-20, MCF7, MD-MBA231, SKBR3
and ZR75-1 were obtained from the American Type
Culture Collection (Manassas, VA). To establish stable
cell lines, SKBR3 cells (1.5 × 10
5)w e r eg r o w no n
60 mm
2 culture dish containing RPMI-1640 medium
supplemented with 10% FCS, 1% glutamine, 1% peni-
cillin and streptomycin (Biochrom-Seromed, Germany)
at 37°C one day before transfection. Siah1, Siah-1L or
Siah1ΔR plasmids were transfected into cells using the
FuGENE 6 transfection reagent (Roche, Mannheim,
Germany) according to the manufacturer’sp r o t o c o l .
Cells were allowed to rest for about 12 to 18 h after
transfection, and the medium was changed with
800 μg/mL of G418 (Invitrogen) for 2 weeks. Stable
clones were selected for G418 resistance and screened
for Sial1 protein level with immunoblotting.
The small interfering RNA (siRNA) duplexes were
designed and purchased from Qiagen (Cambridge, MA,
USA). The sequences for the Siah1 siRNA were: Siah1
siRNA 5′-AACTCCTGCCTCCTTATGTATTT-3′.S i a h 1
siRNA-2, 5′-GAUAGGAACACGCAAGCAA-3′;S i a h 1
siRNA-3, 5′-GUUGCAUGUAGUAACACUA-3′.Ac o n -
trol siRNA was used as well (no silencing): 5′-
AAGAGCCGTCAGACTGCTACA-3′. Roti-Fectplus was
used fro the transient transfections with SIAH1 siRNA,
or control siRNA, according to the manufacturer’s
instructions (Carlroth, Karlsruhe, Germany).
Immunoblotting
Cells were washed in PBS and lysed in NP40 buffer con-
taining 50 mM Tris-HCl, 1 mM PMSF, 150 mM NaCl,
1% NP-40 and protease inhibitor cocktail (Roche Diag-
nostics). After determination of the amount of protein
in the cell lysates, samples were then resolved by polya-
crylamide gel (PAGE) and electrophoretically blotted
onto polyvinylidene difluoride membranes as described
previously [20]. Membranes were incubated with anti-
FLAG-M5 monoclonal antibody (1:500, Sigma Science,
Hamburg, Germany). After incubation with a horserad-
ish-conjugated goat anti mouse antibody, the protein
content was visualized using enhanced chemilumines-
cence (Amersham, Freiburg, Germany). Siah1 and Siah2
protein expression was analysed as well using anti-Siah1
(YZ-12, Santa Cruz, CA, USA) and anti-Siah2 (N-14,
Santa Cruz, CA, USA) primary antibodies, respectively
together with the appropriate secondary antibodies. a-
Tubulin monoclonal antibody was used as a control
(1:500, Santa Cruz, CA, USA).
Irradiation (IR)
Single dose of 0, 2, 4, 6 or 8 Gy with a rate of 650 cGy/
min was given using an Elekta Synergy linear accelerator
with 6 MV-photons, at room temperature.
Reverse transcription-PCR
Total RNA was extracted from cultured cells and col-
lected at different time points after IR using RNEasy
protect mini kit (Qiagen, Germany), according to manu-
facturer’s instructions. cDNA synthesis was performed
in a 20 μl reaction volume with 0.5 μgo ft o t a lR N A
using cDNA synthesis kit (Fermentas, USA). The mix-
ture was incubated at 37°C for 1 h followed by 10 min
in 70°C for inactivation of reverse transcriptase. The pri-
mer sequences for amplification of Siah1 and Siah1L
were described previously [21]. The primer sequences
for amplification of Siah1ΔR and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) were as follow: Siah1ΔR
forward primer ACCTCGAAGTGTCCACCATC
and reverse primer ACTGCATCATCACCCAGTCA
(product size, 547 bp); GAPDH forward primer
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AGCTTCCCGTTCTCAGCCTT (product size, 150 bp).
PCR was done using a MyiQ detection system (Bio-
Rad). The PCR conditions were 95°C for 5 min followed
by 35 cycles of denaturation at 95°C for 30 seconds,
annealing at 60°C for 30 seconds, and extension at 72°C
for 1 min.
Apoptosis and clonogenic survival assay
Transfected SKBR3 cells as well as MCF-7 after siRNA
for Siah1, including a control siRNA, were plated into
100 mm
2 dishes and were irradiated (4 Gy). Apoptosis
was analyzed 24 h after IR by flow cytometry using
Annexin V-FITC apoptosis detection kit (Sigma Aldrich,
Munich, Germany). Staining was performed at indicated
time points after IR according to the manufacturer’s
instructions, and flow cytometry was conducted on a
flow cytometer (BD FACScan). Statistical analysis was
performed using WinMDI V2.9 software. Survival curves
were obtained by means of standard colony formation
assay. Transfected SKBR3 and MCF-7 cells were irra-
diated (1 × 10
3) and plated onto 25-mL culture flash for
80 to 100 colonies per flash. After 14 days of incubation,
colonies were fixed with 10% formalin and stained with
crystal violet. Colonies with >50 cells were scored as a
surviving colony. Surviving fraction was calculated as:
(mean colonies counted)/(cells plated) × (plating effi-
ciency), where plating efficiency was defined as (mean
colonies counted)/(cells plated) for unirradiated controls.
Experiments were conducted in triplicate and are pre-
sented as means ± standard deviation (SD) from three
independent experiments. All survival fractions (SF)
were fitted into the linear quadratic model. The ID10
and SD for survival curves in SKBR3 cells were deter-
mined at 10% cell survival. The sensitizer enhancement
ratio (SER) in SKBR3 cells was defined as SER = mean
inactivation dose (radiotherapy)/mean inactivation dose
(plasmid +radiotherapy), as previously described. SER>1
indicate radiosensitization [24-26].
Proliferation Assay
Transfected SKBR3 cells as wells as MCF-7 cells, upon
Siah1 siRNA, were seeded at a density of 1 × 10
4 cells/
well in a 96-well microplate and grown for 6 h and sub-
sequently exposed to 0, 4 and 8 Gy IR. After 24 h of
incubation at 37°C, the cell proliferation reagent WST-1
was added (10 μl/well) in SKBR3 cells for 30 min,
according to the manufacturer’s instructions (Roche,
UK). The reaction product was quantified by measuring
the absorbance using an ELISA reader (HTS 7000, Per-
kin-Elmer, Rodgau, Germany) and Software HT-Soft
(Perkin-Elmer, USA). The experiments were performed
three times in triplicate and presented as means (± SD).
C e l lv i a b i l i t yc u r v e sw e r ef i t t e du s i n gt h el i n e a r
quadratic model and the dose resulting in 50% of cell
growth inhibition (IC50) was calculated, as previously
described [25,26]. The cell viability of MCF-7 cells was
measured at 2, 4 and 6 days using the same method, as
described above. Cell viability was normalized to the
untreated group. A control siRNA group was included
as well.
Immunofluorescence
Stable transfected SKBR3 cells (5000) were seeded on
cover slips and incubated for 12 h and either unirra-
diated or irradiated with X-ray (4 Gy). At 3 and 6 h
after IR, cells were fixed in cold methanol (-20°C) for
5 min, permeabilized with 1% Triton/PBS for 10 min
and then blocked in PBS containing 0.3% Triton X-100,
3% BSA for 1 h. Fixed, permeabilized cells were incu-
bated with in 100 μL mouse monoclonal anti-gH2AX
antibody at 1:100 dilution (Upstate Biotechnology, Wal-
tham, MA) for 30 min at room temperature. This was
followed by incubation with Alexa 488 conjugated goat
anti-mouse secondary antibody (Molecular Probes,
Eugene, OR, 1:200 dilutions) for 1 h at room tempera-
ture. Finally, cells were counterstained with 4’,6-Diami-
dino-2-phenylindole (DAPI, 0.1 μg/mL). The sections
were mounted with fluorescent mounting medium
(Dako, Germany). The fluorescent images were exam-
ined on an Olympus JMT-2 photomicroscope (Ham-
burg, Germany). For each treatment condition, gH2AX
foci were determined in at least 100 cells.
Invasion assay
In vitro cellular invasion was determined the ability of
cells to invade a synthetic basement membrane (BD
Biosciences, Heidelberg, Germany). Stably transfected
SKBR3 cells (2 × 10
4) and MCF-7 cells (5 × 10
4), upon
Siah1 siRNA, were diluted in 350 μlm e d i u ma n dt r a n s -
ferred into precoated Matrigel membrane filters (8 μm
pore size). The inserts were placed in the bottom cham-
ber containing RPMI 1640 medium supplemented with
5% FCS. Following 48 h incubation at 37°C, filters were
fixed in 100% methanol for 15 min, air dried, and
stained with haematoxylin stain for 2 min. Noninvading
cells on the upper surface were removed with a cotton
swab, whereas invading cells on the underside of the fil-
ter were counted using an inverted microscope. All
e x p e r i m e n t sw e r ed o n ei nt r i p l i c a t ea n dam i n i m u mo f
10 individual fields at ×10 magnification per filter was
counted.
Luciferase reporter assay
Luciferase reporter assays were done at least in triplicate
as described [20]. SKBR3 cells (4 × 10
4) as well as MCF-
7c e l l s( 4×1 0
4), after siRNA, were grown on 24-well
tissue culture plates. In each well, transient DNA
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Lef-responsive luciferase reporter gene (Topflash) or a
negative control (Fopflash), 5 ng of the Renilla luciferase
reporter plasmid (pRL-TK) as an internal control for the
normalization of transfection efficiency and 50 ng of the
indicated expression plasmids or an empty control vec-
tor. After 24 h, the luciferase and Renilla activity was
measured using the dual luciferase assay system (Pro-
mega, Mannheim) and the luciferase activity was nor-
malized against the Renilla luciferase activity and are
presented as means ± SD from three independent
experiments. Together with the Siah1 siRNA group, a
control siRNA was tested as well in MCF-7 cells.
Statistical analysis
Quantitative data were expressed as means ± SD. The
significance of differences between the means was
assessed using one-way ANOVA or student t-test using
SPSS 15.0 software. Statistically significantd i f f e r e n c e
was considered as P < 0.05.
Results
Siah1 gain-of-function in SKBR3 cells and silencing in
MCF-7 breast cancer cells
The expression of Siah1 and its splice variant Siah1L in
breast cancer cell lines was determined using RT-PCR
with specific primers recognizing the common
sequences of both siah1 and siah1L. In line with pre-
vious report [10,27], MCF7 breast cancer cells exhibited
strong expression of Siah1 and Siah1L, whereas BT-20,
MDA-MB-231, SKBR3 and ZR75-1 breast cancer lines
lacked any expression of Siah1 and Siah1L analysed
(Figure 1A). The SKBR3 cells without detectable endo-
genous expression of Siah1 and Sial1L were chosen to
establish stable gene expression. Stable clones were
selected for G418 resistance and screened for relative
equivalent levels of exogenous expression of Siah con-
structs detected by using immunoblotting (Figure 1B).
Additionally, we performed siRNA for Siah1 in MCF-7
to further investigate its role in radiosensitization. Wes-
tern blot confirmed blockade of Siah1 in MCF-7. Off-
target effects can occur during siRNA [28] and therefore
two additional Siah1 siRNAs (siRNA-2 and siRNA-3)
were tested as well. They also confirmed blockade of
Siah1 protein in MCF-7 cells. Control siRNA was used
as well (Figure 2A). Siah2 protein expression was absent
in both SKBR-3 and MCF-7 cells (Figure 2B), as pre-
viously demonstrated [29].
Siah1 determines apoptosis and survival of SKBR3 and
MCF-7 breast cancer cells in response to IR
Whether Siah1 may have an effect on radiation
response has not yet been addressed. We therefore
investigated the effects of Siah1 and its splice variants
on breast cancer cells following IR. We found that
overexpression of Siah1 and Siah1L significantly
enhanced IR-induced apoptosis in SKBR3 cells com-
pared with the control transfected with empty vector
while Siah1 ΔR showed a small but non-significant dif-
ference (Figure 3A, control, 44.5 ± 7.9; Siah1ΔR, 53.4.2
± 2.9; Siah1, 62.3 ± 3.5; Siah1L, 70.9 ± 1.5). Notably,
Siah1 and Siah1L increased apoptosis also in unirra-
diated group (p < 0.05; control, 12.2 ± 9.5; Siah1ΔR,
27.2 ± 13.0; Siah1, 52.3 ± 5.6; Siah1L, 52.5 ± 4.5).
Importantly, siRNA for Siah1 resulted in reduced
apoptosis in response to IR as compared to the
untreated group (Figure 3B, untreated, 31.27 ± 3.9;
control siRNA 29.87 ± 4.5; Siah1 siRNA, 17.04 ± 2.1)
while in unirradiated group no difference was observed
(Fig 3B). To further analyze the radiosensitizing ability
of Siah1 and Siah1L, we used clonogenic assay to
Figure 1 Expression of Siah1 and Siah2 in SKBR3 cells.A :A l l
but the MCF-7 breast cancer cells lacked expression of Siah1 and
Siah1L. mRNA expression was determined by RT-PCR. GAPDH was
used as an internal control. B: Ectopic expression of Siah1, Sial1L or
Siah1ΔR in SKBR3 cells. Cells were stable transfected with plasmids
encoding FLAG- tagged Siah1, Sial1L or Siah1ΔR proteins. Protein
level was determined by Immunoblot analysis with anti FLAG
antibody.
Figure 2 Knockdown of Siah1 expression in MCF7 cells.A :
Western blot showed that siRNA as well as siRNA-2 and siRNA-3 for
Siah1 resulted in suppressed protein expression in MCF-7 cells. B:
Siah2 expression is decreased in SKBR3 and MCF-7 cells. a-Tubulin
was used as an internal control.
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Importantly, overexpression of Siah1L and Siah1 coop-
erated with IR to reduce clonogenic growth of SKBR3,
as compared with irradiated control cells (p < 0.05;
Figure 4A). As illustrated in Table 1, a SER10 of 1.87
was observed with Siah1L gain-of-function, indicating
ah i g h l yc o o p e r a t i v ea n dp o t e n tially synergistic fashion
between Siah1L and IR. Siah1 induced a rather additive
than synergistic radiosensitizing effect (SER10 of 1.26)
while no significant difference in survival was noted
with Siah1ΔR (Table 1). In addition, Siah1 and Siah1L
reduced clonogenic survival also in unirradiated cells,
as compared with the control group. Loss-of-function
for Siah1 by siRNA demonstrated a significant reduc-
tion in the radiosensitivity of MCF-7 cells, even at a
dose of 2 Gy, as assessed by clonogenic survival (Fig-
ure 4B; p < 0.05). To exclude the possibility of “off-tar-
get” effects [28], we tested the impact of Siah1
silencing in radiosensitivity of MCF-7 cells by using
two additional siRNAs (Siah1 siRNA-2 and Siah1
siRNA-3). The latter revealed results similar to the
main Siah1 siRNA used (Figure 4B), whereby a
significant decrease (p < 0.05) in radiosensitivity was
detected.
Siah1 regulates viability in SKBR3 and MCF-7 breast
cancer cells
To determine the effect of Siah1 on the cell viability of
SKBR3 cells after IR, SKBR3 cells were irradiated with
different single doses (0, 4 or 8 Gy) and incubated for
24 h. The overexpression of Siah1 and Siah1L resulted
in a significant dose-dependent reduction of the prolif-
eration of unirradiated as well as irradiated cells, as
compared with control vector (Figure 5A, p < 0.05).
Potentially synergistic enhancement of radiocytotoxicity
with a SER50 of 4.65 for cell viability was observed when
Siah1L was combined with IR (Table 2). The prolifera-
tion assay indicated that the expression of Siah1 also
results in increased sensitivity to ionizing radiation but
less potently. As shown, Siah1ΔR exhibited no effect
with a SER50 of 0.99 (Table 2). Moreover, Siah1 siRNA
revealed an increase in MCF-7 cell viability at 2, 4 and 6
days upon suppression of Siah1 activity (Figure 5B; p <
0.05). Control siRNA was used as well.
Figure 3 Effect of Siah1 gain-of-function and silencing in IR-induced apoptosis. SKBR3 cells were transfected with indicated plasmids and
irradiated with 0 and 4 Gy IR. Apoptosis was determined at 24 h after IR by FACS analysis. Columns, mean of three independent experiments;
bars, SD; *, P < 0.05. Siah1 functions were silenced by siRNA. A control siRNA was used as well. Apoptosis was determined at 24 h after IR by
FACS analysis. Columns, mean of three independent experiments; bars, SD; *, Siah1 siRNA vs. both untreated and control siRNA at 4 Gy, P < 0.05.
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IR exposure
To gain insight into the molecular mechanisms of radio-
sensitization of Siah and to investigate its effect on the
initial DNA damage response to IR we monitored the
fate of double-strand breaks (DSBs) in stable transfected
cells after IR (4 Gy) using gH2AX, a landmark marker
of DSBs [30,31]. Induction of gH2AX foci was signifi-
cantly increased in Siah1- and Siah1L-transfected cells
at 3 h post-IR compared with cells transfected with
empty vector (p < 0.01; Figure 6A). Furthermore, Siah1L
prolonged the persistence of gH2AX foci at relatively
high levels at 6 h post-IR as compared with control
cells, suggesting inhibition of DNA repair (p < 0.01;
Figure 6A and 6B).
Figure 4 Effect of Siah1 on the clonogenic survival of SKBR3
and MCF-7 cells after IR. Cells transfected with indicated plasmids
were irradiated with a single dose of 2, 4 or 6 Gy. Unirradiated cells
(0 Gy) were used as control. A: Siah1 and more potently Siah1L
decreased clonogenic survival in both irradiated and control cells.
Colonies greater than 50 cells were counted and clonogenic survival
was determined by crystal violet staining 14 days after IR. Lines,
mean of three independent experiments; bars, SD; *, P < 0.05. B:
siRNA for Siah1 resulted in reduced radiosensitivity of MCF-7 cells in
response to IR. Silencing of Siah1 by siRNA-2 and siRNA-3 revealed
results similar to the main Siah1 siRNA. Lines, mean of three
independent experiments; bars, SD; *, P < 0.05.
Table 1 Effect of the expression of Siah genes and
radiation on cell survival
IC10 ± SD (Gy) SER10
Control 5,8 ± 0,3 1.00
Siah1 4,6 ± 0,1 1.26
Siah1L 3,1 ± 0,2 1.87
SiahΔR 5,6 ± 0,2 1.03
IC10: Irradiation dose at 10% of cell survival; SD: Standard deviation; SER10:
Sensitizer enhancement ratio at 10% cell survival.
Figure 5 Effect of Siah1 on SKBR3 and MCF-7 cell viability.
Metabolic activity was assessed by WST assay on SKBR3 cells
transfected with indicated plasmids and escalating doses of IR (0, 4
and 8 Gy) as well as in MCF-7 cells after siRNA for Siah1. A: Cell
viability was significantly reduced upon Siah1 and Siah1L
transfection, both in irradiated and control cells. The WST assay was
done 24 h after IR and normalized to unirradiated control. Lines,
mean of three independent experiments; bars, SD; *, P < 0.05. B;
Siah1 siRNA potently increased cell viability in MCF-7 cells at the
different time points tested. Columns, mean of three independent
experiments; bars, SD; *, Siah1 siRNA vs. both untreated and control
siRNA, P < 0.05.
Table 2 Effect of the expression of Siah genes and
radiation on cell viability
IC50 ± SD (Gy) SER10
Control 9,3 ± 0,3 1.00
Siah1 6,6 ± 0,2 1.41
Siah1L 2,0 ± 0,2 4.65
Siah1ΔR 9,4 ± 0,3 0.99
IC50: Irradiation dose at 50% of cell viability inhibition; SD: Standard deviation;
SER10: Sensitizer enhancement ratio at 10% cell survival.
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breast cancer cells
In an effort to define the significance of expression of
Siah1 on the biological behaviour of breast cancer, we
performed cell invasion study with a modified Boyden
chamber assay. Siah1 and Siah1L gain-of-function in
SKBR3 cells, upon transfection, significantly reduced the
ability of these cells to invade Matrigel compared with
control vector (p < 0.05; Figure 7A). Siah1ΔRt r a n s f e c -
tion displayed a less potent but still significant effect
(control, 19.5 ± 2.3; Siah1ΔR, 14.4 ± 3.5; Siah1, 7.8 ±
0.7; Siah1L, 4.6 ± 1.4); (Figure 7A and 7B).
Siah1 siRNA displayed a significant increase of the
number of invading MCF-7 cells, as compared with the
untreated and the control siRNA group (untreated, 38 ±
4; control siRNA, 40 ± 8; Siah1 siRNA, 147 ± 16) (p <
0.05; Figure 8A and 8B).
Siah1 mediates Tcf/Lef activity in SKBR3 and MCF-7
breast cancer cells
Previous studies have demonstrated the role of Siah-1 in
degradation of b-catenin and in reduction of activity of
Tcf/Lef transcription factor [11,13]. To examine the effect
of Siah1 and Siah1L on Tcf/Lef activity in SKBR3 cells, we
performed a luciferase reporter assay. In this assay, a
reporter plasmid with a mutated Tcf/Lef-binding site was
used as negative control. Siah1L gain-of-function signifi-
cantly decreased Tcf/Lef activity while Siah1 showed a
lower but significant effect, as compared with control
SKBR3 cells (p < 0.05; Figure 9A). Tcf/Lef activity was not
affected by overexpression of Siah1ΔR (control, 20.5 ± 2.2;
Siah1, 15.7 ± 0.9; Siah1L, 5.5 ± 2.9; Siah1ΔR, 19.0 ± 1.6)
(p > 0.05; Figure 9A). As expected, Siah1 siRNA demon-
strated increased Tcf/Lef activity in MCF-7 cells, as
assessed by the luciferase assay (Figure 9B, p < 0.05).
Figure 6 Influence of Siah1 on DNA damage in response to IR.A :t r a n s f e c t e dS K B R 3c e l l sw e r ei r r a d i a t e dw i t has i n g l ed o s eo f4G y
followed by immunofluorescence at the 3 and 6 h after IR. Unirradiated cells were used as control. Siah1L significantly increased gH2AX foci at
3 h and the latter were more persistent and numerous 6 h post-IR. Quantitative analysis of gH2AX foci per cell averaged over 100 cells per data
point. Columns, mean; bars, SE; *, P < 0.01. B: Representative merged images of DAPI (blue) and gH2AX (red) at 3 h and 6 h post-IR are shown.
Scale bars, 10 μm.
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Due to intrinsic resistance of many tumors to estab-
lished therapies, including radiotherapy, current
attempts to improve the survival of cancer patients lar-
gely depend on strategies to increase tumor cell sensitiv-
ity. Siah1 has been studied for use in the therapy of
human breast cancer and a number of different geneti-
cally-engineered Siah1 variants have been constructed in
an effort to enhance chemotherapy efficacy [10,22,32].
In recent years, the proteasome pathways have been
searched for the development of new targeted therapies
and chemosensitizers in cancer therapy [33]. However,
their potential to increase the therapeutic efficacy of
radiation therapy and/or to reduce radiation-mediated
side effects remains largely unknown. In the present
study, we investigated whether Siah1 also plays a direct
role in mediating radiation response. We found that
gain-of-function for Siah1, and especially its splice var-
iant Siah1L, sensitized SKBR3 breast cancer cells to the
cytotoxic effects of IR while siRNA for Siah1 decreased
radiosensitivity in MCF-7 breast cancer cells. We
showed that overexpression of Siah1L resulted in a sig-
nificantly increased rate of spontaneous and radiation-
induced apoptosis and decreased SKBR3 cell viability.
Accordingly, Siah1 siRNA exerted opposite effects in
regards to apoptosis and cell viability in MCF7-cells. In
addition, Siah1 increased DNA double-strand breaks
Figure 7 Effects of Siah1 expression on invasion of SKBR3 cells.
A: The invasion of SKBR3 cells was studied in a modified Boyden
chamber assay. A significant decrease in invasion was detected in
transfected SKBR3 cells relative to control group. Cell numbers were
counted in 10 individual high-powered fields. Columns, mean; bars,
SD; *, p < 0.05. B: Representative photomicrographs Magnification
×20.
Figure 8 Effects of Siah1 knockdown on invasion of MCF-7 cells. C: Siah1 siRNA resulted in significant increase in MCF-7 cell invasion. D: Cell
numbers were counted in 10 individual high-powered fields. Columns, mean; bars, SD; *, p < 0.05, Siah1 siRNA vs. both untreated and control
siRNA.
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Page 8 of 11induced by IR in SKBR3 cells, and finally resulted in an
increased radiosensitivity as determined by the clono-
genic survival assay. These effects were more pro-
nounced after overexpression of Siah1L. Similarly, Siah1
siRNA revealed enhanced clonogenic survival of MCF-7
cells in response to IR. Our data support the potentially
synergistic effect of the Siah1L modalities. In vitro
experiments using proliferation and clonogenic assays
showed synergistic cytotoxicity in SKBR3 breast cancer
cells. These findings highlight the notion that suscept-
ibility of human cancer to cytotoxic therapies critically
depends on intact proteasomal-ubiquitin degradation
pathways [32,33]. Weber et al. have previously showed
that the proteasome inhibitor bortezomib can sensitize
head and neck cancer cells to IR [34]. Moreover, Cao
et al. revealed that bortezomib combined with docetaxel
sensitized Bcl-2-overexpressing human prostate cancer
cells to IR [35]. Furthermore, Celastrol, a proteasome
inhibitor, sensitized prostate cancer cells to IR, both in
vitro and in vivo, by impairing DNA damage processing
and augmenting apoptosis [36]. Thus, targeting ubiqui-
tin-proteasome pathway targets, such as Siah1 and
Siah1L, may significantly alter treatment response
Another major finding of this study is that transfec-
tion with Siah1 and Siah1L could suppress SKBR3 breast
cancer cell invasiveness while Siah1 siRNA potently
increased invasiveness in MCF-7 cells. Siah1ΔRo v e r e x -
pression showed less potent effect. In a previous study,
it has been shown that Siah1 is directly inhibited by
BAG-1 (Bcl-2-associated athanogene-1), a heat shock
protein 70 (Hsp70)-associated antiapoptotic protein [12].
Additionally, BAG-1 has been shown to promote cell
migration through cooperation with cytoskeletal pro-
teins such as actin and cytokeratin [37]. Thus, Siah1
gain-of-function could reverse the latter effect. Our data
are similar to a recent study which demonstrated
increased proliferation, decreased apoptosis and
increased invasion of Siah1 siRNA in MCF-7 breast can-
cer cells [38]. In that work, Wen et al. showed that the
JNK and ERK signaling pathways may play an important
role in the Siah1-mediated cell apoptosis and invasion,
respectively. b-catenin can function as an oncogene
when it is translocated to the nucleus, binds to Tcf/Lef
family members and transactivates its target genes [39].
Additionally, b-catenin is involved in breast cancer for-
mation and/or progression and may serve as a target for
breast cancer therapy [40]. Since b-catenin forms a
complex with a member of the Tcf/Lef family and acti-
vates the target genes, reporter assays were performed
to monitor Tcf/Lef dependent gene expression in the
presence or absence of Siah-1L or Siah-1. Notably, over-
expressing Siah-1 and Siah1L in SKBR3 cells resulted in
a reduction in the relative Tcf/Lef transcriptional activ-
ity. These findings are in line with previous reports indi-
cating that Siah-1 and Siah1L regulate Tcf/Lef activity
[20-22]. Notably, functional inhibition of Siah1 by
siRNA upregulated Tcf/Lef activity in breast cancer
cells, in accordance to previous reports [20,41].
The repair of DNA double-strand breaks after ionizing
radiation may account for the apoptotic response and
ultimate radioresinsitivity of malignant breast cancer
cells, even though other mechanisms cannot be excluded.
Importantly, suppression of Tcf/Lef activity, an important
transcriptional factor in regulation of gene expression has
been shown to occur after Siah1L overexpression [21].
Phosphorylation of H2AX seems to play a critical role
in the recruitment of repair- and damage-signalling fac-
tors to the site of DNA breaks [30]. Employment of
gH2AX has been extensively used to monitor the extent
of DSB induction and analyse the effectiveness of novel
biological therapies [31]. The number of foci correlates
with the DNA damage in the nucleus and loss of
gH2AX foci has been in cells within 6 hours after IR
[42]. In line with this finding, we found that Siah1L pro-
longed the persistence of gH2AX foci even at 6 h post-
IR as compared with control cells, as indicated by a
higher amount of gH2AX foci in cells with stable Siah1L
Figure 9 E f f e c t so fS i a h 1o nT c f / L e fr e g u l a t e dt r a n s c r i p t i o n
activity in SKBR3 and MCF-7 cells. A: Transfected cells were
cotransfected with Topflash or Fopflash plasmid, the Renilla
luciferase reporter plasmid (pRL-TK) as an internal control and the
indicated expression plasmids. Luciferase activity was measured at
24 h after transfection and plotted after normalizing with respect to
the Renilla luciferase activity. Each experiment was performed at
least three times. Columns, mean; bars, SD; *, p < 0.05. B; Functional
inhibition of Siah-1 ubiquitin-ligase by siRNA increased TCF/Lef
transcriptional activity in MCF-7 cells at 24 hours after transfection.
Each experiment was performed three times. Columns, mean; bars,
SD; *, Siah1 siRNA vs. both untreated and control siRNA p < 0.05.
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Page 9 of 11overexpression. Thus, both the Siah1L-induced attenua-
tion of proliferation rate and the impaired post-IR DNA
damage repair, may well have contributed to the induc-
tion of apoptosis. These findings are also in good corre-
lation with the reduced survival of these cells, indicting
potentially lethal DNA damage in Siah1L-transfected
SKBR3 cells after IR. Importantly, the increased clono-
genic survival of MCF-7 cells detected after silencing of
Siah1 post-IR highlights the key role of Siah1 in deter-
mining response of breast cancer cells to radiotherapy.
Conclusions
In summary, our findings show for the first time that
Siah1 significantly potentiates radiation response in
breast cancer. We showed that this effect is more pro-
nounced using its splicing variant Siah1L that exhibited
potentially synergistic activity in combination with
radiotherapy against breast cancer cells. The possible
underlying mechanisms by which Siah1 and Siah1L may
decrease cell survival upon radiation exposure seem to
be multifaceted. Our results suggest that gene therapeu-
tic or pharmacological approaches enhancing Siah1 and
Siah1L in tumors with absent expression of these genes
could increase the therapeutic ratio for breast cancer
and have important implications for the development of
novel strategies in radiotherapy.
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